Evidence was from an unpublished phase 3 study (n=343) in people with rheumatoid arthritis, which was included in the European public assessment report (EPAR) for Remsima (subcutaneous). For the ...
It may contain inaccuracies due to the limitations of machine translation. A new nanotechnology has been developed that can dramatically reduce the administration time and frequency of TNF-α (Tumor ...
Celltrion has released the results of its Phase 3 clinical trial for 'Remsima SC', a treatment for autoimmune diseases. The results showed that antibodies were formed in both the intravenous (IV) and ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion Healthcare today announced that the European Commission has approved Remsima SC ™ (CT-P13 SC, biosimilar infliximab) for patients with RA. 1 Remsima SC ...
South Korean biosimilar firm Celltrion will establish a direct sales network for its drugs worldwide, and specifically Remsima SC -- a subcutaneous version of Remsima -- in an effort to secure price ...
South Korean biopharmaceutical company Celltrion said Monday that the European Medicines Agency has accepted for review its Remsima SC -- a subcutaneous version of Remsima, a Celltrion-developed ...
The anti-TNF drug works by targeting a protein in the body called TNF-alpha. Celltrion has revealed data from its Remsima SC (infliximab) trials, evaluating a subcutaneous (SC) biosimilar version of ...
Celltrion announced on the 28th that the market share of its autoimmune disease treatment 'Remsima SC (ingredient name infliximab)' has more than quintupled in the European market within four years of ...
INCHEON, South Korea--(BUSINESS WIRE)--Today, Celltrion Healthcare announced two new data sets on the SC formulation of infliximab, Remsima ® (CT-P13) in IBD, at the European Crohn’s and Colitis ...
Celltrion's autoimmune disease treatment "Remsima injection" ranked No. 1 in domestic pharmaceutical production value for the second straight year. On the 14th, according to the pharmaceutical and ...
Celltrion Launches Remsima IV Liquid Formulation, Securing New Competitive Edge in Infliximab Market
Celltrion has launched the liquid formulation of 'Remsima' (active ingredient: infliximab) in Europe, aiming to strengthen its leadership in the infliximab market. The infliximab liquid formulation is ...
As with all biologic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, Remsima (subcutaneous) would be prescribed and initiated in secondary care. Unlike intravenous infliximab, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results